PBAC's latest decision on Apremilast: Recommended with restriction (2023). Considered for Severe chronic plaque psoriasis in patients who have failed treatment with, or who are contraindicated or intolerant to, methotrexate.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
11
first 2015
Submissions
11
2015 → 2023
Eligible population
Adults aged 18 years or older with severe chronic plaque psoriasis who have failed treatment with, or are contraindicated or intolerant to, methotrexate.
Therapy area
Dermatology
Line of therapy
Second-line
Evidence base
Other
Economic model
Not modelled
ICER note
This is a Category 3 submission requesting changes to treatment criteria only (expansion of eligible prescriber types); no new economic evaluation was undertaken.
ICER (historical)
$15k/QALY–$45k/QALY in an earlier submission (2016) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2015: Not recommended · Authority Required
Mar 2015: Not recommended · Authority Required
Nov 2015: Not recommended · Restricted
Nov 2016: Recommended with restriction · Authority Required — ICER $45k/QALY
Mar 2017: Not recommended · Authority Required
Nov 2017: Recommended with restriction · Restricted
Mar 2018: Recommended with restriction · Restricted
Jul 2020: Recommended with restriction · Authority Required
Mar 2022: Recommended with restriction · Authority Required
Mar 2023: Recommended with restriction · Authority Required
Nov 2023: Recommended with restriction · Authority Required